Phase I study of imatinib mesylate (IM) and sorafenib (S) in patients (pts) with refractory castration-resistant prostate cancer (CRPC). Background: A digital rectal examination (DRE) is less commonly ...

NEW ORLEANS – The accuracy of prostate-specific antigen (PSA) screening for prostate cancer could be improved by accounting for genetic factors that cause changes in PSA levels that are not associated ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

Prostate-specific antigen (PSA) testing may not accurately pinpoint levels at which transgender women on estrogen therapy may be at risk of developing prostate cancer, according to data from the ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Men with a normal PSA upon repeat testing had a 78% lower risk of prostate cancer diagnosis than men with a second abnormal PSA result. For men with an elevated PSA, re-testing PSA levels within a ...